Changes in ctDNA can predict long-term outcomes in certain patients with metastatic CRC on immune checkpoint inhibitors.

Using ctDNA test results to guide adjuvant treatment with pembrolizumab can provide benefits in patients with dMMR solid tumors, data suggest.

DMMR colorectal cancer is characterized by genetic mutations which make it easier for the immune system to identify. The drugs resulted in a “major pathological response,” reducing tumor size ...

MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced that the first patient has been dosed in its Phase ...

Deficient MMR (dMMR) in colorectal cancer (CRC) occurs as a result of inherited or sporadic abnormalities. Phenotypic characteristics, such as proximal anatomical location, mucinous features ...

DNA mismatch repair (MMR) status is one of the most well-established biomarkers in colorectal cancer (CRC). The DNA MMR system helps maintain genetic fidelity, and when defective, genetic errors ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

Key Takeaways. Dostarlimab treatment led to complete clinical responses in 82% of patients with dMMR tumors, avoiding surgery for most. Recurrence-free survival at two years was 92%, with a median ...

Another study shows good results with neoadjuvant immunotherapy in patients with locally advanced dMMR/MSI-H colorectal cancer, leading the authors to suggest it as a new standard of care.

Results showed that in the dMMR/MSI-H population (n=122), treatment with dostarlimab plus carboplatin-paclitaxel reduced the risk of disease progression by 71% vs placebo plus carboplatin ...

Opdivo (nivolumab) plus Yervoy (ipilimumab) improved progression-free survival (PFS) compared to Opdivo alone in patients with mismatch repair deficient (dMMR) or microsatellite instability-high ...

PHILADELPHIA, June 03, 2024--Jemperli trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced dMMR rectal cancer ...